[ Sentien Biotechnologies raises $12M in Series A ]
Sentien Biotechnologies has raised $12 million in Series A funding.
Founded in 2008, Sentien Biotechnologies is a preclinical stage regenerative medicine company that is developing cell based therapies for critical care.
The Series A round will be used to fund initial clinical development of Sentien’s SBI-101 for the treatment of acute kidney injury (AKI).
|Founder / CEO||Brian Miller|
|Mass Medical Angels|
|MBL Venture Capital|
|Boehringer Ingelheim Venture Fund|